Eagle Pharmaceuticals (EGRX) Misses Q2 EPS by $1.80

Eagle Pharmaceuticals (NASDAQ: EGRX) reported Q2 EPS of $1.56, $1.80 worse than the analyst estimate of $3.36. Revenue for the quarter came in at $74.1 million versus the consensus estimate of $116.95 million.

For earnings history and earnings-related data on Eagle Pharmaceuticals (EGRX) click here.

You May Also Be Interested In

• FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
• CVG to join Russell 2000 and Russell 3000 indexes June 26
• BofA lists top 5 themes driving next $1tn in incremental semi sales